戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 asic understanding of transplant biology and immune monitoring.
2  humoral immunity and can be used to improve immune monitoring.
3 thways may aid in risk-stratification and in immune monitoring.
4 ogeneity for more comprehensive and accurate immune monitoring.
5 ollective responses and can be leveraged for immune monitoring.
6 t patients and may be a potential marker for immune monitoring.
7 ll be dependent on developing strategies for immune monitoring.
8 provide valuable tools for immunotherapy and immune monitoring.
9 nical practice, but no regulations exist for immune monitoring.
10 e-cell level, advancing clinical research in immune monitoring.
11 or basic immunological research and clinical immune monitoring.
12    The results may be utilized for improving immune monitoring after allergen immunotherapy and for d
13                              Cytomegalovirus immune monitoring allows an individualized approach to C
14                                  Exploratory immune monitoring analysis of baseline and post-treatmen
15 uggest that these cells can be harnessed for immune monitoring and adoptive immunotherapy in kidney t
16 rm represents a new and informative tool for immune monitoring and clinical assessment.
17 underlying technologies for high-dimensional immune monitoring and discusses aspects necessary for th
18  cells from PBL of cancer patients, enabling immune monitoring and immunotherapies.
19 ts as a standard toolbox in routine clinical immune monitoring and immunotherapy.
20 focus on postinfusion care, as it relates to immune monitoring and infection prevention.
21 dynamic properties of T cells should improve immune monitoring and inform strategies for therapeutic
22 n be measured rapidly, with implications for immune monitoring and intervention in immunocompromised
23 betes (T1D) immunopathogenesis and to design immune monitoring and intervention strategies in relatio
24 e data support the use of [(18)F]FAC PET for immune monitoring and suggest a wide range of clinical a
25 nabling earlier treatment while facilitating immune monitoring and surveillance.
26 boration of improved clinical strategies for immune monitoring and the identification of novel therap
27 mulation blockade, providing new targets for immune monitoring and therapeutic intervention.
28 s, will facilitate selection of peptides for immune monitoring and vaccine development.
29 eral blood samples were collected to perform immune monitoring and whole-exome sequencing (WES).
30 ans and provide the rationale for predictive immune-monitoring and conditioning of the immune reperto
31 dies with personalized drug dosing, improved immune monitoring, and better patient selection should b
32 le tool for immunological research, clinical immune monitoring, and immunotherapeutic applications.
33 ng-term transplant outcomes, optimization of immune monitoring, and quality-of-life outcomes were rev
34 ntial to serve as these sorts of markers for immune monitoring, and thereby assist with patient manag
35 nce with antiviral prophylaxis, VZV-specific immune monitoring, and vaccination to mitigate HZ after
36 in late-phase response (LPR) and exploratory immune monitoring as surrogate markers of therapeutic re
37 itopes should be of considerable utility for immune monitoring, as they cannot reflect an immune reac
38                        ImmuKnow is a general immune-monitoring assay that may help guide therapy.
39  across individuals, raising the prospect of immune monitoring before intervention.
40 is and has potential as a minimally invasive immune monitoring biomarker.
41        Emerging results indicate that T-cell immune monitoring by cytokine enzyme-linked immunosorben
42                  PBMCs were taken weekly for immune monitoring by tetramer analysis and functional as
43                      With repeated sampling, immune monitoring creates a real-time portrait of the ce
44           We review the mechanism of action, immune-monitoring, dosing strategies, combinations, obst
45                                              Immune monitoring during therapy showed that autoimmunit
46 tory brain lesions throughout the 2 years of immune monitoring following treatment was associated wit
47 elate that may guide immunogen selection and immune monitoring for clinical efficacy trials.
48 unosuppressed patients, including individual immune monitoring for protection of this vulnerable grou
49 e duration of prophylaxis was shorter in the immune-monitoring group (adjusted difference, -26.0 days
50 all, 193 patients were randomized (92 in the immune-monitoring group and 101 in the control group), o
51 26 of 87 (adjusted percentage, 30.9%) in the immune-monitoring group and in 32 of 98 (adjusted percen
52 lly anti-inflammatory, with implications for immune monitoring, immune interventions (including vacci
53 s offers significant potential for improving immune monitoring in both clinical practice and research
54                                              Immune monitoring in cancer immunotherapy involves scree
55 immune environments could allow longitudinal immune monitoring in cancer.
56                               Spatiotemporal immune monitoring in clinical trials and reverse transla
57 ensional cytometry is an innovative tool for immune monitoring in health and disease, and it has prov
58 tional and developmental analyses as well as immune monitoring in health and disease.
59             These data underscore a role for immune monitoring in patients with HER2-positive IBC to
60 emand that quality regulations be applied to immune monitoring in the future.
61  and/or therapeutic vaccine construction and immune monitoring in the TRAMP mouse model that may prov
62 ovel antigen-targeting probes during dynamic immune monitoring in vitro and in vivo.
63  end point was PSA response at 6 months, and immune monitoring included measurements of anti-PSA and
64 a duration of antiviral prophylaxis based on immune monitoring (intervention) or a fixed duration (co
65                                              Immune monitoring is experimental in nature, usually per
66               Regardless of the conventional immune monitoring methods applied in the post-transplant
67 tied into the development and performance of immune monitoring methods.
68                                              Immune monitoring models integrating multiple functions
69                                  KEY POINTS: Immune monitoring models integrating multiple functions
70                               Currently, the immune monitoring necessary for predicting the presence
71                                         Such immune monitoring needs to be incorporated in larger stu
72              The results suggest that serial immune monitoring of alloreactivity might be beneficial
73 These techniques will be useful not only for immune monitoring of cancer vaccine trials, but also for
74                                        Thus, immune monitoring of coronavirus disease 2019 might be o
75 d by HLA-DQ2/8 heterozygosity and may assist immune monitoring of disease progression and therapeutic
76 ications in predictive model development and immune monitoring of HIV-1 vaccine trials.
77                                          The immune monitoring of islet transplant recipients include
78 nd IFN-gamma- and IL-2-producing T cells for immune monitoring of kidney transplant recipients before
79 tal components by dedicated receptors allows immune monitoring of loss of cellular integrity.
80                                              Immune monitoring of otherwise healthy infants with RSV
81 itro stimulation improved the sensitivity of immune monitoring of patients immunized with synthetic p
82           These findings provide a basis for immune monitoring of patients with MS and suggest that t
83 ire gives promise to the possibility of both immune monitoring of the autoimmune components in RA and
84  immunotherapies and strategies for clinical immune monitoring of their effectiveness.
85        These results suggest an approach for immune monitoring participants undergoing immunotherapy
86                                              Immune monitoring posttreatment showed an increase in ef
87              As an example of the "Treg MLR" immune monitoring potential, addition of third component
88  tissue samples for cancer immunotherapy and immune-monitoring purposes.
89                                    Regarding immune monitoring, reduced CD8 T cell activation markers
90                              High-throughput immune monitoring requires methods to produce and charac
91                                              Immune monitoring resulted in a significant reduction of
92                                 Longitudinal immune-monitoring reveals remodeling of the T-cell recep
93 s in both rare and common cells across human immune monitoring settings.
94 ed patterns of immune system behavior across immune monitoring settings.
95                                              Immune monitoring showed that there were no changes in t
96 g knowledge and discuss how state-of-the-art immune monitoring strategies could potentially permit no
97 mise toward the goal of in vivo, noninvasive immune monitoring strategies for evaluating cancer immun
98 point, patient responses were established by immune monitoring strategies to detect subtle changes in
99 ion, we have developed a novel and versatile immune monitoring strategy by adding a short cysteine-ri
100 we focus on recent insights from genetic and immune monitoring studies of patients that are refining
101 esponse rate, progression-free survival, and immune monitoring studies.
102                                              Immune-monitoring studies demonstrated that cytoreductiv
103 lysis of 130 patients who had enrolled in an immune monitoring study, we correlated acute rejection r
104                            Recipients in the immune-monitoring study (n=10) displayed>80% depression
105                                              Immune monitoring suggested that these antitumor T-cell
106 ts imply further applications to blood-based immune monitoring systems and predictive biomarkers for
107 eceiving chemoradiotherapy using genomic and immune monitoring technologies.
108 ed tissue is essential to move this emerging immune monitoring technology from the bench to the bedsi
109 rovide unique, time-dependent signatures for immune monitoring that are less compromised by the timin
110 ents in various clinical trials will require immune monitoring that is reliable and comparable so tha
111           During cycle 1, patients underwent immune monitoring to assess the effect of IL-2 on lympho
112 onal study of cytomegalovirus (CMV)-specific immune monitoring to direct the length of antiviral prop
113                                              Immune monitoring to predict long-term outcome should in
114 PBMCs by ELISPOT has potential utility as an immune monitoring tool.
115 s the importance of implementing single-cell immune monitoring tools in early phases of drug developm
116  induction that will be guided by innovative immune monitoring tools.
117         We review recent developments in CMV immune monitoring, vaccination, and monoclonal antibodie
118  and look forward to the role that vaccines, immune monitoring, viral kinetics and new antiherpesviru
119 inating preanalytical errors associated with immune monitoring, we have defined the protein signature
120 c disease and recent initiatives to optimize immune monitoring will facilitate rational design, monit
121  CML (NordCML007, NCT01725204), we performed immune monitoring with single-cell RNA and T cell recept

 
Page Top